Geminii

Geminii is an AI-native biotechnology company dedicated to transforming drug discovery through the integration of advanced artificial intelligence and high-throughput experimental biology. Founded by industry veterans, the company leverages its proprietary platform to identify novel targets and develop precision medicines across multiple therapeutic areas, including oncology and immunology. Geminii aims to accelerate the transition from data to clinic by utilizing deep learning models to decode complex biological systems. The company operates with a global footprint, maintaining research and development facilities in both the United States and China. By combining generative AI with robust wet-lab validation, Geminii seeks to improve the success rates and efficiency of the drug development process.